X4 Pharmaceuticals Announces $125 Million Capital Infusion From $105 Million Sale of Priority Review Voucher and $20 Million Drawdown From Existing Loan Facility
X4 Pharmicals宣佈通過出售1.05億美元的優先審查憑證和從現有貸款機制中提取2000萬美元的資金注入1.25億美元
X4 Pharmaceuticals Announces $125 Million Capital Infusion From $105 Million Sale of Priority Review Voucher and $20 Million Drawdown From Existing Loan Facility
X4 Pharmicals宣佈通過出售1.05億美元的優先審查憑證和從現有貸款機制中提取2000萬美元的資金注入1.25億美元
使用瀏覽器的分享功能,分享給你的好友吧